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Purpose: The PAX6 gene was first described as a candidate for human aniridia. However, PAX6 expression is not re-
stricted to the eye and it appears to be crucial for brain development. We studied PAX6 mutations in a large spectrum of
patients who presented with aniridia phenotypes, Peters’ anomaly, and anterior segment malformations associated or not
with neurological anomalies.
Methods: Patients and related families were ophthalmologically phenotyped, and in some cases neurologically and
endocrinologically examined. We screened the PAX6 gene by direct sequencing in three groups of patients: those affected
by aniridia; those with diverse ocular manifestations; and those with Peters’ anomaly. Two mutations were investigated by
generating crystallographic representations of the amino acid changes.
Results: Three novel heterozygous mutations affecting three unrelated families were identified: the g.572T>C nucleotide
change, located in exon 5, and corresponding to the Leucine 46 Proline amino-acid mutation (L46P); the g.655A>G
nucleotide change, located in exon 6, and corresponding to the Serine 74 Glycine amino-acid mutation (S74G); and the
nucleotide deletion 579delG del, located in exon 6, which induces a frameshift mutation leading to a stop codon (V48fsX53).
The L46P mutation was identified in affected patients presenting bilateral microphthalmia, cataracts, and nystagmus. The
S74G mutation was found in a large family that had congenital ocular abnormalities, diverse neurological manifestations,
and variable cognitive impairments. The 579delG deletion (V48fsX53) caused in the affected members of the same family
bilateral aniridia associated with congenital cataract, foveal hypolasia, and nystagmus. We also detected a novel intronic
nucleotide change, IVS2+9G>A (very likely a mutation) in an apparently isolated patient affected by a complex ocular
phenotype, characterized primarily by a bilateral microphthalmia. Whether this nucleotide change is indeed pathogenic
remains to be demonstrated. Two previously known heterozygous mutations of the PAX6 gene sequence were also de-
tected in patients affected by aniridia: a de novo previously known nucleotide change, g.972C>T (Q179X), in exon 8,
leading to a stop codon and a heterozygous g.555C>A (C40X) recurrent nonsense mutation in exon 5. No mutations were
found in patients with Peters’ anomaly.
Conclusions: We identified three mutations associated with aniridia phenotypes (Q179X, C40X, and V48fsX53). The
three other mutations reported here cause non-aniridia ocular phenotypes associated in some cases with neurological
anomalies. The IVS2+9G>A nucleotide change was detected in a patient with a microphthalmia phenotype. The L46P
mutation was detected in a family with microphthalmia, cataract, and nystagmus. This mutation is located in the DNA-
binding paired-domain and the crystallographic representations of this mutation show that this mutation may affect the
helix-turn-helix motif, and as a consequence the DNA-binding properties of the resulting mutated protein. Ser74 is lo-
cated in the PAX6 PD linker region, essential for DNA recognition and DNA binding, and the side chain of the Ser74
contributes to DNA recognition by the linker domain through direct contacts. Crystallographic representations show that
the S74G mutation results in no side chain and therefore perturbs the DNA-binding properties of PAX6. This study
highlights the severity and diversity of the consequences of PAX6 mutations that appeared to result from the complexity of
the PAX6 gene structure, and the numerous possibilities for DNA binding. This study emphasizes the fact that
neurodevelopmental abnormalities may be caused by PAX6 mutations. The neuro-developmental abnormalities caused by
PAX6 mutations are probably still overlooked in the current clinical examinations performed throughout the world in
patients affected by PAX6 mutations.
511 The PAX6 gene was first described in 1991 as a candi-
date for human aniridia [1]. This congenital abnormality is a
bilateral panocular disorder affecting 1 in 64,000 to 96,000 in
the general population. It is characterized by the absence of
an iris and is associated with other eye abnormalities includ-
ing cataract, optic nerve malformations, coloboma, and foveal
hypoplasia (OMIM 106210). These defects are shared with
the small eye (Pax6+/-) mouse, a model of the human syn-
dromes. PAX6 is also involved in other anterior segment mal-
formations in addition to aniridia and associated anomalies
including Peters’ anomaly [2]. Embryonic development of the
eye is affected in cases of Peters’ anomaly, leading to corneal
clouding and variable iridolenticulocorneal adhesions that may
occur as an isolated ocular abnormality or together with other
ocular defects.
The PAX6 gene (NC_000011) is located on chromosome
11p13, and homologues have been found in diverse species.
The gene contains 14 exons, one of which is alternatively
spliced. Pax6 protein is a transcription factor containing three
highly conserved domains (Figure 1), and there are two major
isoforms: Pax6(-5a), comprising 422 amino acids, and
PAX6(+5a), comprising 436 amino acids resulting from the
insertion of a 14 amino acid-long sequence in the paired do-
main (PD). This insertion abolishes Pax6 DNA-binding prop-
erties [3] and seems to induce, when the Pax6(+5a) isoform is
overexpressed, a developmental cascade modifying the neu-
ronal architecture of the retina [4].
The PD comprises two separate helix-turn-helix motifs
that form two subdomains (Figure 1): a NH2-terminal
subdomain (NTS) and a COOH-terminal subdomain (CTS)
that act on different target sequences [3]. The PD and the bind-
ing homeodomain (HD) recognize different DNA-binding se-
quences, and thus Pax6 has the potential to recognize diverse
DNA-binding sites in a large variety of target genes.
PAX6 is expressed in the developing iris, lens, ciliary
body, corneal epithelium, and retina. Upon completion of eye
development, PAX6 expression remains in the neural retina,
the lens epithelium, and the cornea. Furthermore, in combina-
tion with additional transcription factors, the level and spatial
distribution of PAX6 expression in the developing eye are im-
portant for the establishment of the eye axes. For example,
PAX2-PAX6 is critical in defining the optic stalk/optic cup
boundary, while PAX6-cVAX and TBX5 expression mediates
dorsoventral patterning of the eye [5]. A dose-dependent ef-
fect of the PAX6 gene product has been described and the range
of eye abnormalities seems to correlate with the level of PAX6
activity [6]. However, PAX6 expression is not restricted to the
eye. It is the only PAX gene expressed in the telencephalon,
the diencephalon, in the caudal part of the rhombencephalon,
in the myelencephalon and in the spinal cord. It appears to be
crucial for brain development [7]. However, it is not expressed
in the mesencephalon [8]. The PAX6 gene is also expressed in
the postnatal and adult brains [9] and in the pancreas [10].
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Figure 1. Structure of the PAX6 gene.  PAX6 contains three highly
conserved domains: a 128 amino acid DNA-binding paired domain
(PD), a 60 amino acid DNA-binding homeodomain (HD), which binds
different DNA target sequences, and a Proline-Serine-Threonine
(PST)-rich transactivation domain.
512The expression pattern of the PAX6 gene is consistent with
both the combination of diverse ocular phenotypes observed
and the distribution of neurological manifestations in isolated
patients (sporadic cases) and in pedigrees (familial cases) with
PAX6 mutations. Impairment of PAX6 activity will obviously
affect the expression patterns of its target genes, and there is
substantial evidence of associations between PAX6 mutations,
brain development abnormalities, cognition disorders [11], as
well as pancreatic endocrine disorders [12].
We screened a large spectrum of patients who presented
with aniridia phenotypes, Peters’ anomaly, and other anterior
segment malformations. We report three new mutations and
two known mutation of the PAX6 nucleotide sequence. We
describe in detail one familial mutation of the PAX6 gene as-
sociated with a complex phenotype involving ocular malfor-
mations and neurodevelopmental anomalies. We also report
an intronic nucleotide change, IVS2+9G>A, in a patient with
a microphthalmia phenotype. In addition, we report two pre-
viously identified nonsense mutations, Q179X and C40X.
METHODS
Patients:  All participants gave their informed consent accord-
ing to the Bioethics Laws of the European Union and France,
and according to the Helsinki Declaration. The families were
recruited in the “Département d’Ophtalmologie, Centre
Hospitalier Necker-Enfants Malades” (France), in the “Institut
de Recherches en Ophtalmologie” (Switzerland) and in
“Hôpital Erasme” (Belgium). We screened the PAX6 gene in
78 persons, from 0 to 73 years (affected patients and in most
instances their relatives), including unrelated families and
apparently isolated cases. The patients were classified into three
groups. Group 1 was composed of 36 patients (22 isolated
patients and 14 affected members belonging to three unre-
lated families) who were affected by aniridia associated or
not with other abnormalities. Group 2 contained 10 patients
with Peters’ anomaly. Group 3 comprised 32 patients (13 ap-
parently isolated patients and 19 affected members belonging
to two different families), who were suffering neither aniridia
nor Peters’ anomaly but were affected by diverse ocular and,
in some cases, neurological anomalies. We also established a
control group of 200 unrelated normal individuals devoid of
any eye disease, who were screened for PAX6 nucleotide
changes. Table 1 gives the ages of the affected patients at the
time of phenotyping.
All the patients included in this report submitted to a thor-
ough ophthalmic examination. Some patients also underwent
a neurological examination, brain magnetic resonance imag-
ing (MRI) and a complete systematic neurological and endo-
crinological evaluation (tests for follicle-stimulating hormone
[FSH], luteinizing hormone [LH], adreno-corticotrophic-hor-
mone [ACTH], prolactin, growth hormone, somatomedin C,
thyroid-stimulating hormone [TSH], cortisol, estradiol con-
centrations, synacthene, and luteinizing hormone-releasing
hormone [LHRH]).
Intelligence Quotient testing:  The Intelligence Quotient
values of all the affected and nonaffected members of the large
family F were measured using the Stanford-Binet IQ test ver-
sion 5.
DNA amplification and sequencing:  DNA was extracted
from blood lymphocytes by a proteinase K digestion technique.
Each exon of the PAX6 gene was amplified from genomic DNA
by polymerase chain reaction (PCR) using primers chosen by
ourselves and those described by Love et al. [13] and detailed
in Table 2. PCR used 60 ng of each patient’s genomic DNA as
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TABLE 1. AGES OF AFFECTED PATIENTS
We indicate in this table the ages of patients at the time of their first clinical phenotyping, in the University Hospital of Lieges, Belgium, in the
Jules Gonin Hospital of Lausanne, Switzerland as well as in the Necker-Enfants Malades Hospital of Paris (Case A, Family B, Family C, Case
D, and Family E). All Family F members were examined in the Hospitals of Dôle, Besançon, and Dijon. Two patients from Family F were
initially examined in the Necker-Enfants Malades Hospital of Paris. Asterisk indicates the ages of affected patients during their phenotyping,
which was performed in November 2003 at the Hospitals of Dôle, Besançon, and Dijon within the framework of this study. For patients F-I-
2 and F-II-2, now deceased, the ages of the diagnosis were not available (dashes).
513a template, 20 pmol of each primer, 10 mM Tris-HCl at pH
8.3, a MgCl2 concentration depending upon the exon ampli-
fied, 50 mM KCl, 1.5 units of Thermophilous aquaticus (Taq)
DNA polymerase, and dNTP. PCR consisted of 30 cycles and
was carried out in an automated MJC thermal cycler (PTC
225). All fragments were purified using the Concert kit using
NucleoFast 96 PCR plates and then analyzed by direct se-
quencing using an ABI PRISM 3100 DNA sequencer.
Crystallographic views:  We analyzed the crystallographic
structures of some of the mutant proteins to visualize the con-
sequences of the amino acid changes (missense mutations).
All crystallographic views were obtained and derived from
the structural model determined from X-ray diffraction (PDB
id:6PAX). The structures of the mutated residues were gener-
ated using SwissProt PDB viewer and viewed in Rasmol or
PyMol.
RESULTS
 In Group 1, which contained patients affected by aniridia, we
found a novel mutation and two previously described PAX6
mutations. In Group 3, composed of patients with diverse ocu-
lar manifestations and some associated neurologic abnormali-
ties, we found two novel mutations and an intronic nucleotide
change. However, we did not find any PAX6 mutations in
Group 2, which was composed of patients with Peters’
anomaly. All identified PAX6 mutations are summarized in
Table 3.
Mutations found in Group 1:  We  found a 972C>T
(Q179X) transition (Figure 2) in isolated case A, who had pre-
sented with bilateral aniridia and no other associated abnor-
mality.
Family B consisted of six members of which one was a
stillborn child (II-2; Figure 2). We identified a 555C>A (C40X)
mutation in exon 5 in two affected patients, I-2 and II-1. Both
presented with bilateral aniridia associated with bilateral cata-
racts, nonvascularized corneal opacities, and bilateral glau-
coma that was more severe in patient II-1 than in patient I-2.
Both underwent endocrinological examinations that revealed
a low ACTH concentration exclusively in patient II-1.
Family C consisted of three members (Figure 2). Affected
members I-2 and II-1 carried a heterozygous 579delG
(V48fsX53) mutation in exon 6. Both of the affected mem-
bers presented with bilateral aniridia associated with bilateral
congenital cataract, bilateral foveal hypolasia, and nystagmus.
Mutations found in Group 3:  In isolated case D, we iden-
tified a heterozygous IVS2+9G>A nucleotide change (Figure
2). This patient presented with a microphthalmia phenotype
associated with bilateral congenital microcornea, powdered
cataract, nystagmus, and partial sclerocornea, as well as a band-
shaped keratitis in the left eye. The examination of this pa-
tient under general anesthesia, when he was one year old, al-
lowed us to estimate the axial length of his right eye at a value
of 12 mm and the axial length of his left eye at a value of 13
mm. The visual electrophysiological investigations (electro-
oculogram, electro-retinogram and visual-evoked potentials)
and the brain computed tomography scan were surprisingly
normal.
Family E consisted of four members. We found an 572T>C
(L46P) mutation in exon 5 of affected patients I-1, II-1 and II-
2 (Figure 2). These patients had presented with bilateral mi-
crophthalmia associated with bilateral congenital cataract, bi-
lateral glaucoma. and nystagmus. All affected patients of this
family had an abnormally shaped and shortened anterior cham-
ber and were at risk of closed-angle glaucoma. In addition,
they had a strong myopia (greater than or equal to 5 diopters).
The axial measurements of the distance between the posterior
face of the lens and the retina were abnormally high and al-
ways superior to 23 mm in all affected patients of this family
and completely compatible with the degree of myopia detected
in each patient’s eye. We previously did not find any PITX2
nor FOXC1 mutation in these patients. We investigated con-
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TABLE 2. LIST OF PRIMERS USED AND THE PCR PRODUCT SIZE
Exon   Primer       Sequences (5'-3')       Amplicon
----   ------   -------------------------   --------
1      1F       AGGGAACCGTGGCTCGGC            207
       1R       GGGTGAGGGAAGTGGCTGC
2      2.1F     TTATCTCTCACTCTCCAGCC          178
       2.1R     CTGTTGTTGCTTGAAGACCAC
       2.2F     AAACTCTCACCAGCAACTCC          197
       2.2R     GGAGACCTGTCTGAATATTGC
3      3F       GGACGTATGCTGTTGAACCAC         166
       3R       TGAGCCCAAAGCAGCCACCA
4      4F       TGCAGCTGCCCGAGGATTAA          133
       4R       CCGAAGTCCCAGAAAGACCA
5      5.1F     CTCTTCTTCCTCTTCACTCTG         163
       5.1R     CGCTGTGAGCTAGCTCTAC
       5.2F     CGGTGGTGTCTTTGTCAACG          170
       5.2R     AGAGGGCGTTGAGAGTGG
5a     5aF      CTCTACAGTAAGTTCTCATACC        173
       5aR      GGAAGTGGACAGAAAACCAC
6      6.1F     TGGTTTTCTGTCCACTTCCC          167
       6.1R     GCACTCCCGCTTATACTGG
       6.2F     CCGAGAGTAGCGACTCCAG           184
       6.2R     AGGAGAGAGCATTGGGCTTA
7      7.1F     GTGAGCTGAGATGGGTGA            175
       7.1R     CTTCCGGTCTGCCCGTTC
       7.2F     ATGGGCGCAGACGGCATG            171
       7.2R     GACAGGCAAAGGGATGCAC
8      8.1F     CCCTTTTGGAGGCTCCAAG           185
       8.1R     GATGTTCTATTTCTTTGCAGC
       8.2F     TCCAACGGAGAAGATTCAG           176
       8.2R     TCTTTGTACTGAAGATGTGGC
9      9F       GGAGGTGGGAACCAGTTTGA          195
       9R       GTGAAACTGCACAGTCTCTC
10     10.1F    CTCGACGTAGACACAGTGC           175
       10.1R    AATTGGTTGGTAGACACTGG
       10.2F    TCAGAGAAGACAGGCCAGC           153
       10.2R    CCCGGAGCAAACAGGTTTAA
11     11F      GGGCTCTGACTCTCACTCTG          191
       11R      TTATGCAGGCCACCACCAGC
12     12.1F    GCTGTGTGATGTGTTCCTCA          168
       12.1R    GACTGTTCATGTGTGTCTGC
       12.2F    CTGCATGCTGCCCACCAG            163
       12.2R    AAGAGAGATCGCCTCTGTGC
13     13F      CATGTCTGTTTCTCAAAGGG          202
       13R      CCATAGTCACTGACTGAATTAACAC
For each pair of primers, the amplicon size is indicated in base pairs.
F: forward primer; R: reverse primer. Exons 2, 5, 6, 7, 8, 10, and 12
were amplified in two overlapping fragments. In each case, primer
pair (.1F and .1R) amplifies the most upstream 5' part of the target
genomic DNA, and primer pair (.2F and .2R) amplifies the most
downstream 3' part of the target genomic DNA encompassing the
specific exonic sequences. Sequences are given in the 5'-3' direction.
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Figure 2. Pedigrees and mutation sequences in the PAX6 gene.  Males and females are represented by squares and circles, respectively, and
affected family members are darkened symbols. Partial DNA sequence chromatographs of PAX6 genomic sequences from affected individuals
in two isolated cases (A and D) and in four unrelated families (B, C, E and F) are shown. The accurate mutations in families and isolated
patients were indicated as closely as possible to each sequence and their names were provided according to the international nomenclature for
human gene mutations. The nucleotide numbering of the mutations was based on the sequence of the PAX6(-5a) isoform.
TABLE 3. SUMMARY OF DETECTED MUTATIONS AND CHANGES
We show the pedigrees of the affected patients whenever they were available with certainty. We also indicate the sequence of the six mutations
reported in this study. Each mutation is associated with the affected patients from the clinical group 1 corresponding to aniridia phenotypes or
from the group 3 corresponding to other ocular phenotypes associated in one large family (F) with neurological anomalies. A and D are
isolated cases whereas B, C, E, and F refer to familial cases (see Figure 2). The exon in which the mutated amino acid residue is located is
mentioned. Each mutation is named according to the nucleotide change and the corresponding amino acid modification for the two major
isoforms: Pax6(-5a), comprising 422 amino acids, and PAX6(+5a), comprising 436 amino acids resulting from alternative splicing.
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Figure 3. Crystallographic views of leucine 46 to proline mutation found in family E.  Represented are the interactions between DNA (blue)
and the helix-turn-helix motif affected by the amino acid change (red) in the wild-type protein (A) and in the mutated protein (B). The mutated
Leu 46 is located just after the second helix in the NH2-terminal subdomain of the PAX6 paired domain (PD). The substitution of a proline for
a leucine modifies the structure of the second helix and affects the HTH motif conformation. This could alter the position of the third helix,
which recognizes the DNA. The readers should be aware that we standardized the numbering of the amino acid residues of the paired domain.
We allocated a number to each amino acid residue that corresponded to its location vis-a-vis the first methionine, initiating the PAX6 short
protein isoform (-5a). However, the X-ray crystallography specialists use to allocate a numbering to the amino acids of the PAX6 PD which
starts at the first amino acid of this PD.
Figure 4. Crystallographic
views of the serine 74 to gly-
cine mutation found in family
F.  Represented are the inter-
actions between the DNA
(blue) and PAX6 PD red. A and
B show global views while C
and D represent magnified
views of the linker region of
the PD (residue 61-76) in
which the mutated Ser74 is lo-
cated. This region makes many
contacts with the minor groove
of the DNA strand. In the wild-
type protein (A and C), the Ser-
74 (red) side chain contacts the
DNA. In the mutated protein
(B and D), the amino acid
change leads to the loss of the
side chain and increases the
distance between the target ge-
nomic DNA and the PAX6
linker domain, making direct
contact between DNA and
PAX6 impossible.
516sequences of this PAX6 mutation by generating crystallo-
graphic views of the amino acid change. The mutated L46 is
located in the NH2-terminal subdomain of the PAX6 PD, just
after the second helix (Figure 3A). The substitution of a leu-
cine by a proline (Figure 3B) modifies the structure of the
second helix and affects the helix-turn-helix (HTH) motif con-
formation.
Family F consisted of 36 members, distributed in five gen-
erations, of whom 14 members were affected by a 655A>G
(S74G) mutation in exon 6 (Figure 2). The S74G mutation
resulted in no side chain, and crystallographic analysis (Fig-
ure 4) shows a distance increase between the DNA and the
atoms of the PAX6 PD. Most patients presented either with
minor or major bilateral foveal hypoplasia (Figure 5C and Fig-
ure 5D) or, in some rare instances, either macular coloboma
or a major posterior coloboma (Figure 5E and Figure 5F). All
affected members presented with congenital bilateral multidi-
rectional nystagmus probably due to foveal or macular alter-
ations. Moreover, they also displayed either a congenital cata-
ract (rarely) or, more commonly, a precocious infantile pro-
gressive bilateral cataracts with substantial phenotypic vari-
ability between the affected family members (Figure 5). Some
of the patients had highly unusual ophthalmic phenotypes,
which in a few cases differed bilaterally. Several affected pa-
tients of this family suffered neurodevelopmental defects and/
or mental retardation and/or epilepsy. At least four patients V-
6, V-7, V-11, and V-14, had epileptic seizures confirmed dur-
ing their sojourn in the hospital. Some affected patients pre-
sented with permanent cognitive impairments associated with
neurological abnormalities, detected with certainty at birth for
patients V-6 and V-7. At least since birth, patient V-7 suffered
a general cortical atrophy associated with a large cyst of the
septum lucidum separating the horns of the lateral ventricles.
Patients IV-5 and V-7 presented with spontaneous multidirec-
tional nystagmus aggravated by different movements of ocu-
lar globes and a moderately static cerebellar syndrome. Brain
MRI imaging of patient IV-5 revealed a hypoplasia of the an-
terior commissure (Figure 6C) and the absence of the pineal
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Figure 5. Biomicroscopic ob-
servations in affected patients
from the family F who carry
the PAX6 serine 74 to glycine
mutation.  A and B show slit
lamp aspects of the ocular an-
terior segment as well as of the
lens of patient IV-5. C, D, E,
and F are funduscopy photo-
graphs of the foveal hypopla-
sia of patient IV-8 (C and D)
and the colobomas in patient V-
11 (E and F).
517gland (Figure 6). Patient IV-8 had signs of a mild pyramidal
syndrome, whereas patient V-6 presented with unambiguous
pyramidal syndrome. All patients from this family were ex-
amined by two separate neurologists in two different hospi-
tals. All affected members of this family presented with a mild
cerebellar syndrome, which in some affected patients was clini-
cally obvious spontaneously without any additional clinical
examination required for diagnosis confirmation. To this con-
stant neurological abnormality, the severity of which could
vary significantly from one affected patient to the other, were
unfrequently associated neurological manifestations includ-
ing epilepsy. The cognitive impairments and an abnormal con-
trol of emotivity were constantly present in all affected mem-
bers of this family. The IQ testing of all affected and unaf-
fected members of the large family F provided IQ values con-
stantly just below the normal values in most affected mem-
bers, but low IQ values in some severely affected patients.
None of the unaffected patients presented any abnormal IQ
value. None of the family members who did not carry the
mutation displayed any neurological or cognitive impairment
nor any abnormal control of humor or emotivity. Endocrino-
logical investigations showed patient IV-5 had a low response
and patient IV-8 a blunted response to the synacthen test.
DISCUSSION
 The nucleotide mutations we report in Group 1 are associated
with both sporadic (case A) and familial cases of aniridia (cases
B and C). These patients have various aniridia phenotypes,
with various associated ocular disorders. All these associated
anomalies fall within the wide clinical spectrum of abnormali-
ties often observed in cases of aniridia.
The first mutation, Q179X, we describe (case A) is a pre-
viously known mutation [14]. It appeared that the patient car-
ries a de novo mutation or that one of his parents has a germi-
nal mosaicism for this mutation. The mutation leads to a pre-
mature stop codon that truncates the paired domain close to
its COOH-terminal part.
The nucleotide change identified in family B introduces
a stop codon (C40X) that truncates PAX6 within the NH2-
terminal half of the PD. This mutation is a recurrent protein
truncation mutation that is always associated with aniridia, as
seen in a search of the Human PAX6 Allelic Variant Database.
Patient II-1 presented with a low ACTH concentration. This
phenotype can be explained by the expression of the PAX6
gene in the hypothalamus. This mutation could lead to a deg-
radation of mRNA by nonsense-mediated decay. In this case,
no truncated protein would be produced. However, some
mRNA harboring premature stop codons escape the degrada-
tion pathway and make truncated protein synthesized [15]. If
the altered mRNAs are not degraded by nonsense-mediated
decay and are translated, the mutated protein would lack the
C-terminal subdomain of the PD and the homeo- and PST-
domains. We suggest that the resulting 36 amino acid polypep-
tide cannot bind normally to the genomic DNA target se-
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Figure 6. Brain MRI abnormalities in patient IV-5 from family F with the PAX6 serine 74 to glycine mutation.  We show different MRI views
of patient IV-5 from family F. A, B, and C correspond to MRI horizontal views, while D and E correspond to MRI sagittal views. MRI in A
shows a small structure that might correspond to the habenula (arrow). MRI in B, D, and E reveals the absence of the pineal gland (arrow).
MRI in C shows hypoplasia of the anterior commissure of the brain (arrow).
518quences. Thus, the resulting protein is unlikely to have the
transactivating activities that are crucial for normal eye de-
velopment.
In family C, we identified a deletion, 579delG, that cre-
ates a frameshift in the reading and introduces a stop codon in
position 53 (V48fsX53). If the altered mRNAs are not de-
graded by nonsense-mediated decay and are translated, the
mutated protein would only contain 52 amino acids of the NH2-
terminal part of PAX6. The resulting truncated protein would
lack the homeo- and PST-domains and would certainly be non-
functional.
In many affected patients from Group 1, we did not de-
tect any mutations in exons of the PAX6 gene, although PAX6
is, thus far, the only gene associated with aniridia. These re-
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Figure 7. Amino acid sequence alignment of the human PAX6 paired domain.  A shows alignment of human PAX6 protein sequence with
seven other species: Takifugu rubripes, Lineus sanguineus, Rattus norvegicus, Mus musculus, Drosophila melanogaster, Gallus gallus, and
Danio rerio. The PAX6 PD is highly conserved throughout species. The amino acids affected by mutation in the PD reported in this study are
shown in color. B shows the PD amino acid sequence alignment of all PAX genes (PAX1-5 and PAX7-9). The amino acids affected by
mutation in the PD reported in this study are shown in color. The PD is highly conserved troughout all PAX proteins.
519sults can be explained by the technique used in this study as
well as by a possible overlooked clinical bias in patient re-
cruitment for this study. Mutations may be located outside the
studied genomic region, in enhancers or silencers, in the pro-
moter region, or in distant intron sequences, for example. We
can increase the detection rate using several techniques: South-
ern blotting, quantitative genomic PCR, illegitimate RT-PCR
with total RNA extracted from lymphoblastoid cell lines or
from white blood cells, and high resolution karyotyping. Fur-
thermore, there are published cases of aniridia-like phenotypes
related to unknown genes [16]. Although PAX6 appears to be
the major, and maybe even the only, gene involved in autoso-
mal dominant aniridia, other aniridia clinical forms may be
due to yet to be identified genes.
We screened ten patients with Peters’ anomaly for PAX6
mutations (Group 2). We found no PAX6 mutation in this group
of patients, whereas the PAX6 mutation database reports sev-
eral additional PD missense changes with the Peters pheno-
type [17]. Peters’ anomaly may be caused by mutations in sev-
eral genes, including PITX2 [18], FOXC1 [19], CYP1B1 [20],
EYA1 [21], and FOXE3 [22]. The phenotype of these patients
is therefore probably a direct consequence of mutations in one
of these genes that are also involved in eye development rather
than to mutations in the PAX6 gene.
As PAX6 is involved in the eye and the central nervous
system development, we studied patients with various ante-
rior segment abnormalities and also neurological impairments,
frank neurological abnormalities as well as mental retarda-
tion (Group 3). We identified an intronic transition
(IV2+9G>A) in sporadic case D belonging to Group 3. This
change is observed in an isolated sporadic case and was not
been found in our control group. Thus, the IV2+9G>A could
likely be a mutation or a rare polymorphism. Additional ex-
periments based on the illegitimate transcription method are
required for demonstrating the pathogenicity of this nucleotide
change. Illegitimate transcription relies upon the RT-PCR of
total RNAs extracted from white blood cells or immortalized
fibroblastic or lymphoblastic cell lines from the patient. It could
allow us to detect possible alternative splicing abnormalities
affecting the length and the sequence of the PAX6 transcripts.
Unfortunately, the materials necessary for performing these
experiments are not available in our laboratory. The occur-
rence of this intronic change and the growing rate of discov-
ery of genuine novel intronic mutations causing several in-
herited diseases highlight the need to study both genomic DNA
and RNA. In so doing, this would increase the likelihood of
identifying disease-causing mutations in intronic sequences.
In family E, we identified a L46P mutation. The residue
concerned is in the NH2-terminal subdomain of the PAX6 PD
(residues 4-63) immediately downstream from the second he-
lix, and is highly conserved between PDs (Figure 7). This
domain has an HTH motif. The third helix recognizes the DNA
binding proteins [23,24]. The L46P mutation is at the end of
the second helix and specifically modifies its structure due to
the proline being in either cis or trans conformation. This mu-
tation affects the HTH motif. This could modify the position
of the third helix, which recognizes the DNA. Figure 3 shows
where the amino acid is located (at the end of the second he-
lix) and is based on the structure obtained by X-ray diffrac-
tion (PDB id:6PAX). The Leu 46 residue does not appear to
directly contact the DNA and thus the DNA-binding activity
of the COOH-terminal subdomain of the PD carrying a mu-
tated leucine at position 46 may be conserved, although the
mutated protein does not express strong transactivation activ-
ity. Chao et al. [25] described a mutation that affects the same
leucine residue (L46R): Two members of a family carried the
same mutation but had different phenotypes, and none of them
had aniridia. This phenotype appears somewhat similar to the
phenotype of our patients, in which the same amino acid resi-
due is mutated, albeit not to the same amino acid. Chao et al.
[25] found that the mutated PAX6 protein did not bind DNA
and was less able than the wild-type PAX6 to transactivate
genes. These results suggest that similar phenotypes, and in
particular phenotypes without aniridia, may be related to mu-
tations affecting the same amino acids of the PAX6 gene, the
major cause of aniridia.
We identified a S74G missense mutation in exon 6 in all
affected members of family F. This residue is in the PAX6 PD
linker region (residues 64 to 79) connecting the NTS and the
CTS. This linker is highly conserved in all known PD pro-
teins (Figure 7), and it makes numerous contacts with the mi-
nor groove of the DNA strand (Figure 4A,B); it is essential
for DNA recognition and DNA binding. Ser74 directly con-
tacts the adenine at position 14, in the oligonucleotide sequence
including the PAX6 binding site, used by Xu et al. [23,24] for
cocrystallization to study the interactions between the PAX6
paired domain and its core target genomic DNA binding se-
quence. This contact is made with no water molecule found
between Ser74 and adenine 14 (Figure 4C,D). Ser74 is essen-
tial for DNA binding, because its side chain contributes to
DNA recognition by the linker domain through direct con-
tacts. The side chain connects with N-3 of adenine 14 and also
with the phosphate group of guanine 15. Any mutation that
leads to a residue without a side chain or with a differently
charged side chain will lead to incorrect DNA binding in this
linker region. The S74G mutation results in no side chain and
thus perturbs the DNA-binding properties of PAX6. In silico,
crystallographic analysis shows that with this mutation, the
distance between the DNA and the atoms of the PAX6 linker
domain are greater than 5Å, which is twice the distance ob-
served for the wild-type, and thus the direct contacts of the
PD with the DNA (adenine 14 or guanine 15) are lost. These
abnormally large distances between atoms of the target DNA
and atoms of the PAX6 PD linker domain may well be the
structural basis of the abnormal DNA-binding properties of
PAX6. Additional biochemical experiments are required for
demonstrating unambiguously the pathogenicity of this muta-
tion at the atomic level and for confirming or invalidating the
pathogenic model supported by our modeling. The major oph-
thalmic manifestations caused by the S74G mutation in all
affected members of family F are bilateral foveal hypoplasia
and bilateral congenital cataract. This unusual ocular pheno-
type caused by the S74G mutation in PAX6 gene is similar to
that described by Hanson et al. [26] and is associated with a
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520G64V substitution affecting a specific glycine amino-acid resi-
due located just beyond the third alpha-helix of the NH2-ter-
minal paired subdomain. Glycine is completely invariant at
this position in all paired domain proteins characterized (Fig-
ure 7). This G64V mutation was described in a family in which
the mother and her two children appeared to have an ocular
syndrome involving presenile cataract and foveal hypoplasia.
The mother had congenital nystagmus with bilateral cataracts
in addition to bilateral foveal hypoplasia and abnormalities of
the peripheral corneal epithelium. The son had bilateral nys-
tagmus from early infancy and bilateral mild lens opacities
later in life. The daughter also had bilateral nystagmus, con-
genital bilateral cataracts, as well as tilted optic discs and bi-
lateral foveal hypoplasia [26]. This report [26] and our obser-
vation of bilateral cataracts in all affected members of family
F highlight the importance of both residues Gly64 and Ser74
in the transactivation properties of the paired domain vis a vis
genes involved in lens development and maintenance of its
transparency. Indeed, PAX6 has fundamental roles in the de-
veloping lens since the earliest stages of its formation as dem-
onstrated by a recent elegant work showing the crucial impor-
tance of PAX6 interactions with transcription factors such as
SIX3 and SOX2 in the induction of the lens placode [27].
Moreover, other genes encoding crystallins are transcription-
ally controlled by PAX6: αA-crystallin, αB-crystallin, γF-crys-
tallin, β-crystallin, and ε-crystallin [28].
The S74G mutation is particularly interesting because it
is associated with unusual ocular phenotypes and, more im-
portant, with a constant cerebellar syndrome in all affected
patients of one large family. Most affected patients of this fam-
ily displayed nearly constantly cognitive impairments with a
low IQ. All unaffected patients of family F have a normal IQ.
Some patients of this family had epilepsy, while others dis-
played variable neurological deficits along with severe cogni-
tive deficiencies. At least one patient of this large family (V-
7) was affected by a severe form of mental retardation with-
out any karyotype abnormality. These clinical manifestations
caused by a mutation in the PAX6 PD highlight the early and
extensive role of PAX6 in eye and central nervous system de-
velopment and its persistent contribution to adult human brain
function. Missense mutations of the PD, such as S74G, con-
siderably impair the interaction of the PD with its DNA target
sequences.
Given the PAX6 gene expression pattern both in mouse
and human during development and adulthood, it is not sur-
prising that such mutations can trigger neurodevelopmental
defects associated with permanent neurological deficiencies
in adults, including anterior commissure hypoplasia, absent
pineal gland (IV-5), static cerebellar syndrome (IV-8), and
moderate to severe pyramidal syndrome as observed in our
patients (IV-8). Patient IV-5 presented with hypoplasia of the
anterior commissure. We must strongly emphasize that all af-
fected patients carrying the S74G mutation in the large family
studied and described partially in this report present with a
constant cerebellar syndrome of variable severity. The vari-
ability of the phenotype observed in this family, including the
variability of the neurological and cognitive deficits or im-
pairments is consistent with the autosomal dominant mode of
inheritance of this mutation. Variable expressivity and incom-
plete penetrance are two well known features of this mode of
inheritance. These features can be explained by genetic
epistratic effects or by other mechanisms beyond the scope of
this report. Furthermore, PAX6 rarely acts alone on any given
target gene or network of target genes. Instead, it acts with
other DNA-binding proteins in complexes involving proteins
belonging to diverse families of transcription factors as well
as cotranscription factors such as other members of the PAX
family e.g., PAX2, members of the SIX family such as SIX3,
members of the dachsund0 family, the EYE ABSENT family,
the SOX family, and other families of transcription factors.
Recent studies using MRI, moreover functional MRI, have
shown that individuals with aniridia and cognition deficits due
to a heterozygous mutation in PAX6 have structural abnor-
malities of the grey matter as well as white matter deficits in
the corpus callosum [11]. A subset of patients affected by PAX6
mutations and presenting with agenesis of the anterior com-
missure was shown to have mild cognitive impairments [29].
The most severely affected patient of this large family, V-7
presented with a dramatic form of mental retardation associ-
ated with neurological manifestations. Sisodiya et al. [30] re-
ported the occurrence of an absence or hypoplasia of the ante-
rior commissure and reduced olfaction in many aniridia cases
without callosal agenesis. They also suggested that PAX6
haploinsufficiency caused more widespread
neurodevelopmental anomalies in humans than first antici-
pated, based on the ocular and neurological observations re-
ported in aniridia patients. Patient V-7 and his mother IV-5
had no pineal gland. One MRI study [31] showed the absence
or hypoplasia of the pineal gland and absence or hypoplasia
of the anterior commissure are common in patients who have
aniridia and known PAX6 mutations with diverse ocular ab-
normalities. This study described more accurately the conse-
quences of PAX6 mutations, including PD missense mutations
that are usually underrepresented in aniridia. Some of the pa-
tients (V-6, V-7, V-11, and V-14) suffered from epilepsy. Epi-
lepsy has also been reported in a study of patients affected by
all types of PAX6 mutations [31]. The affected patient IV-8
presented with an obvious static cerebellar syndrome. This
observation is consistent with data collected in studies of the
Sey (Small eye) mouse, showing that Pax6 is produced in cer-
ebellar granule cells and that PAX6 influences the morpho-
genesis of the whole cerebellum. Mutations in the PAX6 gene
significantly affect cerebellar development [32]. Our results
further support these data and highlight the role of PAX6 mu-
tations in structural brain anomalies and cognitive anomalies.
They also allow these anatomical abnormalities to be linked
to the known roles of murine Pax6 in regional differentiation,
axonal guidance, and other aspects of early forebrain devel-
opment [11]. Pax6 seems to play a crucial role in the develop-
ing central nervous system by transcriptional regulation of
various target genes such as cell adhesion molecules (CAMs),
in particular NCAM, L1CAM R-cadherin, Cadherin 6, and
Cadherin 8. Studies have shown that, in PAX6 mutants, the
expression of these molecules is altered and mutations in these
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[28]. All these data explain how mutations in the PAX6 gene
can, directly or not, lead to cerebral impairments or frank ab-
normalities. In the case of the family reported here, the mem-
bers who did not carry the mutation did not have these impair-
ments. Moreover, the neurological manifestations we describe
have been previously associated in the literature with PAX6
gene mutations. Although these neurological phenotypes might
be caused or influenced, in terms of severity, by nucleotide
variants of other developmental genes coding proteins inter-
acting or not with PAX6, we suggest that the S74G PAX6
mutation might play a causative role, in isolation or not, in the
complete phenotypes reported in this family. We also observed
abnormally lowered or blunted plasma cortisol response to
the synacthen test in two adult patients carrying the S74G
PAX6 mutation. The PAX6 master gene is early expressed in
the anterior neural plate from which the hypothalamopituitary
axis and the retina are derived.
In this study, we report three novel PAX6 mutations: two
previously described mutations and a novel intronic PAX6
nucleotide change of which the pathogenicity is not yet proved
but is likely. We observed in this study that all aniridia pheno-
types corresponded to nonsense mutations or deletions that
led to a premature termination codon, whereas nonaniridia
phenotypes were associated with missense mutations. These
results are in full agreement with the genotype-phenotype cor-
relations reported by Tzoulaki et al. [33]. They examined the
Human PAX6 Allelic Variant Database and found that three-
quarters of aniridia cases were caused by mutations that intro-
duced premature termination codons into the PAX6 open read-
ing frame. Our mutational screening led us to identify four
familial mutations corresponding to two novel transitions: one
previously reported transversion and one base pair deletion.
We also detected nucleotide changes in sporadic cases, one of
which is a previously reported mutation corresponding to a
transition and the other is a novel intronic nucleotide change,
the pathogenicity of which remains to be confirmed. Three of
the mutations were located in the PD (cases A, E, and F), which,
as shown by Prosser and van Heyningen [34], has a higher
mutation rate than the rest of the PAX6 gene. Two of these
mutations, found in cases A and E, were located in the NTS,
whereas the third mutation, found in case F, was in the PD
linker. There is evidence that the different DNA binding do-
mains of PAX6 have different targets, but it has also been
shown that the PD modulates the HD DNA-binding activity
[35]. The two PD subdomains seemed to influence differently
the DNA binding of the HD of PAX6. Singh et al. [35] ana-
lyzed the effects of two missense mutations in the PD, each
one being located in one of the two subdomains. The muta-
tion in the NH2-terminal subdomain resulted in a loss of func-
tion through the PD, but enhanced function mediated through
the HD. The mutation in the COOH-terminal subdomain re-
sulted in a total loss of function of the protein. Thus the sever-
ity and diversity of the consequences of PAX6 mutations ap-
peared to result from the complexity of the PAX6 gene struc-
ture, and the numerous possibilities for DNA binding were
due to the large variety of specific gene targets. It is our opin-
ion that neurodevelopmental abnormalities induced by PAX6
mutations have been underestimated for a long time. These
abnormalities should systematically be investigated both by
clinical examination and MRI imaging in every patient af-
fected by aniridia or any congenital eye abnormality.
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